搜尋
Prelude Therapeutics Inc
PRLD添加自選
3.990USD
-0.320-7.42%
收盤 09-24 16:00（美東）
317.80M總市值
虧損本益比TTM
關於 Prelude Therapeutics Inc 公司
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Prelude Therapeutics Inc 簡介
公司代碼PRLD
公司名稱Prelude Therapeutics Inc
上市日期Sep 25, 2020
CEOVaddi (Krishna)
員工數量131
證券類型Ordinary Share
年結日Sep 25
公司地址175 Innovation Boulevard
城市WILMINGTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編19805
電話13024671280
網址https://preludetx.com/
公司代碼PRLD
上市日期Sep 25, 2020
CEOVaddi (Krishna)
Prelude Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
190.69K
+2.62%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
190.69K
+2.62%
Mr. Sean P. Brusky
Mr. Sean P. Brusky
Chief Business Officer
Chief Business Officer
100.00K
--
Mr. Sean P. Brusky
Mr. Sean P. Brusky
Chief Business Officer
Chief Business Officer
100.00K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+21.87%
常見問題
Prelude Therapeutics Inc的前五大股東是誰？
Prelude Therapeutics Inc的前五大股東如下：Dr. Krishna (Kris) Vaddi, Ph.D.
有多少機構持有Prelude Therapeutics Inc(PRLD)的股份？
截至2026Q1，共有149家機構持有Prelude Therapeutics Inc的股份，合計持有的股份價值約為30.05M，占公司總股份的57.50% 。與2025Q4相比，機構持股有所增加，增幅為-7756404.00。